ArticleBioMed research international2020
CircEIF4G2 Promotes Tumorigenesis and Progression of Osteosarcoma by Sponging miR-218.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Circular RNA in cervical cancer: Fundamental mechanism and clinical potential.Non-coding RNA research · 2024Review
- Retracted: CircEIF4G2 Promotes Tumorigenesis and Progression of Osteosarcoma by Sponging miR-218.BioMed research international · 2024Article
- Circular RNA circBLNK promotes osteosarcoma progression and inhibits ferroptosis in osteosarcoma cells by sponging miR‑188‑3p and regulating GPX4 expression.Oncology reports · 2023Article
- Tumor suppressor miR-218 directly targets epidermal growth factor receptor (EGFR) expression in triple-negative breast cancer, sensitizing cells to irradiation.Journal of cancer research and clinical oncology · 2023Article
- Circular RNA circEIF4G2 aggravates renal fibrosis in diabetic nephropathy by sponging miR-218.Journal of cellular and molecular medicine · 2022Article
- Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression.Signal transduction and targeted therapy · 2021Review
- Review
- Circ_0000527 promotes osteosarcoma cell progression through modulating miR-646/ARL2 axis.Aging · 2021Article
- A Novel Circular RNA circITSN2 Targets the miR-218-5p/LMO7 Axis to Promote Chicken Embryonic Myoblast Proliferation and Differentiation.Frontiers in cell and developmental biology · 2021Article
- Advances in the Biological Functions and Mechanisms of miRNAs in the Development of Osteosarcoma.Technology in cancer research & treatmentReview
Corrections and comments
- Retraction · 2024-03-20Computer-Aided Content or Computer-Generated Content · Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNAs (circRNAs) play a key role in regulating the tumorigenesis and development of human cancers, including osteosarcoma (OS). Of note, the molecular mechanism underlying the progression of OS has remained largely unclear. The present study identified that a novel circRNA circEIF4G2 was upregulated in OS tissues and cells. Moreover, we constructed a circEIF4G2-mediated ceRNA network and revealed that circEIF4G2 was involved in regulating multiple cancer pathways, such as the EGFR signaling pathway, the PI3K-Akt signaling pathway, and the ErbB signaling pathway. Loss-of-function assays showed that circEIF4G2 knockdown significantly suppressed OS cell proliferation, migration, and invasion. Mechanically, we found that circEIF4G2 could directly bind to miR-218, and miR-218 mediated the effect of circEIF4G2 knockdown on OS progression. In conclusion, the present study showed that circEIF4G2 could be a potential biomarker for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.